Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

6
Magenta Therapeutics: This June IPO Should Be On Your Radar

1h seekingalpha
Ease of access to prior funding, institutional participation and strengthening of leadership team are significant green flags.
MGTA NVS GSK PFE

4
Female FTSE 100 bosses earn US$4m less than men

2018-08-19 thestar.com.my
LONDON: Chief executive officers of the biggest London-listed businesses are earning an average of £3mil (US$4mil) less than their male counterparts.
PSN GSK GSK

4
Why Adaptimmune's Forward Momentum May Be The Perfect Entry Point

2018-08-18 seekingalpha
A recent licensing arrangement with a big pharma has seriously de-risked its flagship program, but at a price.
GSK GSK

21
Mylan Suffers a Blow as Teva Gets FDA Nod for EpiPen Generic

2018-08-17 zacks
Mylan (MYL - Free Report) suffered a setback as rival Teva Pharmaceutical Industries Ltd. (TEVA - Free Report) recently won FDA approval for the first generic version of the former’s EpiPen and EpiPen Jr (epinephrine) auto-injector for the emergency treatment of allergic reactions, including those that are life-threatening (anaphylaxis), in adults and pediatric patients.
TEVJF TEVA RDN GSK FAF TEVVF PFE GSK

10
Glaxo, J&J's Dual Drug HIV Regimen Succeeds in Phase III Study

2018-08-17 zacks
GlaxoSmithKline’s (GSK - Free Report) HIV drug subsidiary-ViiV Healthcare and partner Johnson and Johnson (JNJ - Free Report) announced positive headline results from phase III ATLAS study evaluating a two-drug regimen (2DR) for the treatment of HIV.
HD GILD GSK OXY PFE GSK ROK

17
A Synopsis Of The HIV Market

2018-08-16 seekingalpha
Editor's note: Seeking Alpha is proud to welcome Vision and Value as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more »
CYDY GILD JNJ GSK GSK

12
The Battle For Best-In-Class In ATTR Has Begun

2018-08-16 seekingalpha
There will be significant competition for the limited number of ATTR patients - approximately 10k with ATTR-PN, 40k with ATTR-CM, and 200k with ATTRwt.
NTLA EIDX SAP MRK IONS AKCA PRTA PFE GSK ALNY

24
Cloudera: Firing On All Cylinders Despite Sales Execution Fears

2018-08-15 seekingalpha - 2
Cloudera represents an attractive enterprise opportunity, levered to growth in machine learning, AI, and data analytics.
CLDR TRI GSK

4
Hepatitis B vaccine shortage hits Edmonton travel clinics

2018-08-14 cbc.ca
Edmonton travellers hoping to get the hepatitis B vaccine may be out of luck as country-wide supply issues hit the city's travel clinics.
GSK GSK

221
Stocks To Watch: Any Privacy For Tesla?

2018-08-11 seekingalpha - 4
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
SYY DCP DTK FOLD AROC ALLK CRL JWN WPZ STI-A CSCO CCB ABBV RUBY EQIX GILD CNST SYF CZR NVO JNJ MGM VRTX TM AXP NVDA BAC AGN HESM FAF KSU EFX CBU CREE LLY GSK JPM KHC TSLA PLAY DE OMP MYFW JCP TWX SYN SMLP WMT AMAT TWTR CELG WMB GSK VLKAY BAC DFS SQ IDXX BWLD ACOR STI ABBV NTAP CRNX PFE REPL JD HD WIMHY TLRY GM BMY CWH WIMHF F C ESTA A LYB CMCSA M COF WMH MRK LALWF SEMG

63
Liquidia IPO: Phase 3 Clinical Stage That Interested The Bill Gates Foundation

2018-08-08 seekingalpha - 2
Liquidia Technologies, Inc. is a biopharmaceutical company developing products for the treatment of pulmonary arterial hypertension and local postoperative pain.
GLAXF PCRX GSK HRTX GSK DRRX LQDA

22
Mylan (MYL) Q2 Earnings and Revenues Miss, Guidance Cut

2018-08-08 zacks
Mylan (MYL - Free Report) reported dismal results for second-quarter 2018 as earnings and sales both missed estimates. The company also lowered its guidance.
GSK ABBV CVS GSK ABBV

Related Articles

REPH: Recro Pharma Analysis and Research Report

23h - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

23h - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

2018-08-20 - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...

CUSIP: 37733W105